摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

丁二酸1-[2-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)乙基]4-(2,5-二氧代-1-吡咯烷基)酯 | 132774-52-8

中文名称
丁二酸1-[2-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)乙基]4-(2,5-二氧代-1-吡咯烷基)酯
中文别名
——
英文名称
N-((4-(2-Maleimidoethoxy)succinyl)oxy)succinimide
英文别名
4-O-(2,5-dioxopyrrolidin-1-yl) 1-O-[2-(2,5-dioxopyrrol-1-yl)ethyl] butanedioate
丁二酸1-[2-(2,5-二氢-2,5-二氧代-1H-吡咯-1-基)乙基]4-(2,5-二氧代-1-吡咯烷基)酯化学式
CAS
132774-52-8
化学式
C14H14N2O8
mdl
——
分子量
338.27
InChiKey
HLYQBBSYKLLKAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    527.4±60.0 °C(Predicted)
  • 密度:
    1.52±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.8
  • 重原子数:
    24
  • 可旋转键数:
    9
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    127
  • 氢给体数:
    0
  • 氢受体数:
    8

文献信息

  • NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
    申请人:BOUCHARD Hervé
    公开号:US20120225089A1
    公开(公告)日:2012-09-06
    Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.
    本发明提供了隐藻素偶联物及其包含它们的组合物。还提供了制备和使用此类化合物的方法。
  • ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
    申请人:SANOFI
    公开号:US20130137659A1
    公开(公告)日:2013-05-30
    Provided herein are compounds of formula (I):
    本文提供的是式(I)的化合物:
  • MACROMOLECULAR CONJUGATES OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREFOR
    申请人:Verkman Alan S.
    公开号:US20080171793A1
    公开(公告)日:2008-07-17
    Provided herein are bioactive agents comprising a compound that inhibits the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR) and that is linked to a macromolecule that interacts with a cell that expresses CFTR. The bioactive agents described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea.
    本文提供了生物活性剂,其中包括一种抑制囊性纤维化跨膜导电调节因子(CFTR)离子传输活性的化合物,并且与与表达CFTR的细胞相互作用的大分子相连。本文所描述的生物活性剂可用于治疗与CFTR活性异常增加相关的疾病、疾病后遗症和疾病、疾病后遗症和病症,例如分泌性腹泻。
  • Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
    申请人:——
    公开号:US20030134294A1
    公开(公告)日:2003-07-17
    A biologic can be immobilized in a transparent polyurethane-hydrogel composition. Such a polyurethane-hydrogel composition can be prepared from forming a polyurethane-hydrogel mixture and immobilizing a biologic in the mixture. The mixture can be formed by admixing a prepolymer and a water-soluble crosslinker in aqueous solvent and in the substantial absence of organic solvent. A suitable prepolymer generally includes at least one water-soluble polyol and at least one isocyanate and can be added to the mixture in an amount of no greater than about 5 weight percent based on total weight of all components. A suitable crosslinker generally has a crosslinker functionality of at least 2. A biologic includes cells, peptides, nucleics, peptide nucleic acids, saccharides, lipopolysaccharides, glycolipids, and combinations of these. A polyurethane-hydrogel composition having an immobilized biologic can be particularly useful for biomedical applications. Some examples of useful biomedical applications include protein microarrays, cell microarrays, and DNA microarrays.
    生物制剂可以固定在透明的聚凝胶组合物中。这种聚凝胶组合物可以通过形成聚凝胶混合物并将生物固定在混合物中来制备。该混合物可通过在性溶剂中和基本不含有机溶剂的情况下混合预聚物和溶性交联剂来形成。合适的预聚物一般包括至少一种溶性多元醇和至少一种异氰酸酯,添加到混合物中的量不超过所有组分总重量的约 5%。合适的交联剂通常具有至少 2 的交联官能度。生物制剂包括细胞、肽、核酸、肽核酸、糖类、脂多糖糖脂以及这些物质的组合。具有固定生物体的聚凝胶组合物尤其适用于生物医学应用。有用的生物医学应用实例包括蛋白质微阵列、细胞微阵列和 DNA 微阵列。
  • Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applicaions
    申请人:Sandford F. Andrew
    公开号:US20050147994A1
    公开(公告)日:2005-07-07
    A biologic can be immobilized in a transparent polyurethane-hydrogel composition. Such a polyurethane-hydrogel composition can be prepared from forming a polyurethane-hydrogel mixture and immobilizing a biologic in the mixture. The mixture can be formed by admixing a prepolymer and a water-soluble crosslinker in aqueous solvent and in the substantial absence of organic solvent. A suitable prepolymer generally includes at least one water-soluble polyol and at least one isocyanate and can be added to the mixture in an amount of no greater than about 5 weight percent based on total weight of all components. A suitable crosslinker generally has a crosslinker functionality of at least 2. A biologic includes cells, peptides, nucleics, peptide nucleic acids, saccharides, lipopolysaccharides, glycolipids, and combinations of these. A polyurethane-hydrogel composition having an immobilized biologic can be particularly useful for biomedical applications. Some examples of useful biomedical applications include protein microarrays, cell microarrays, and DNA microarrays.
    生物制剂可以固定在透明的聚凝胶组合物中。这种聚凝胶组合物可以通过形成聚凝胶混合物并将生物固定在混合物中来制备。该混合物可通过在性溶剂中和基本不含有机溶剂的情况下混合预聚物和溶性交联剂来形成。合适的预聚物一般包括至少一种溶性多元醇和至少一种异氰酸酯,添加到混合物中的量不超过所有组分总重量的约 5%。合适的交联剂通常具有至少 2 的交联官能度。生物制剂包括细胞、肽、核酸、肽核酸、糖类、脂多糖糖脂以及这些物质的组合。具有固定生物体的聚凝胶组合物尤其适用于生物医学应用。有用的生物医学应用实例包括蛋白质微阵列、细胞微阵列和 DNA 微阵列。
查看更多